↓ Skip to main content

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Overview of attention for article published in BMC Cancer, July 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
Published in
BMC Cancer, July 2022
DOI 10.1186/s12885-022-09802-y
Pubmed ID
Authors

Wei-Jun Fu, Ya-Fei Wang, Hong-Guo Zhao, Ting Niu, Bai-Jun Fang, Ai-Jun Liao, Hai Bai, Jin Lu

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 6%
Researcher 1 6%
Other 1 6%
Student > Doctoral Student 1 6%
Student > Master 1 6%
Other 0 0%
Unknown 11 69%
Readers by discipline Count As %
Medicine and Dentistry 2 13%
Biochemistry, Genetics and Molecular Biology 1 6%
Unspecified 1 6%
Unknown 12 75%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2022.
All research outputs
#19,515,297
of 23,996,152 outputs
Outputs from BMC Cancer
#5,645
of 8,532 outputs
Outputs of similar age
#313,241
of 424,993 outputs
Outputs of similar age from BMC Cancer
#125
of 263 outputs
Altmetric has tracked 23,996,152 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,532 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,993 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 263 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.